Sleep disturbances in Parkinson's disease: the contribution of dopamine in REM sleep regulation.

Nearly all patients with Parkinson's disease (PD) have sleep disturbances. While it has been suggested that these disturbances involve a dopaminergic component, the specific mechanisms that contribute to this behavior are far from being fully understood. In this article, we have reviewed the current understanding of the linkage between sleep and PD, focusing on the participation of the dopaminergic system in the regulation of rapid eye movement (REM) sleep. The presence of an REM sleep behavior disorder in patients with PD might reflect the early involvement of dopaminergic neurotransmission in REM sleep-related structures. Therefore, it has been suggested that these structures are affected by an imbalance of dopamine levels. Several studies have demonstrated that neurons in the substantia nigra pars compacta (SNpc) and in the ventral tegmental area (VTA) are active during REM sleep and that sleep-related disturbances may result when these neurons are targeted by neurotoxins. We discuss current evidence suggesting the presence of a putative reciprocal connectivity between the SNpc, VTA, the pedunculopontine tegmental nucleus and reticular formation, which may exert an important influence on the REM sleep mechanism. This review provides a comprehensive overview of the literature that addresses this challenging and unrecognized component of PD.

[1]  C Gottesmann,et al.  Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep–wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats , 2005, Journal of neuroscience research.

[2]  Helmut Heinsen,et al.  Brainstem pathology and non-motor symptoms in PD , 2010, Journal of the Neurological Sciences.

[3]  James M. Krueger,et al.  Sleep disturbances in the rotenone animal model of Parkinson disease , 2005, Brain Research.

[4]  R G Priest,et al.  Prevalence of narcolepsy symptomatology and diagnosis in the European general population , 2002, Neurology.

[5]  J. Paul Bolam,et al.  Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? , 2004, Trends in Neurosciences.

[6]  A. Negrotti,et al.  A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: Absence of co-morbid association , 2011, Journal of the Neurological Sciences.

[7]  P. Derambure,et al.  MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations , 2008, Experimental Brain Research.

[8]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[9]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[10]  U. Bonuccelli,et al.  New pharmacologic horizons in the treatment of Parkinson disease , 2006, Neurology.

[11]  B. Högl,et al.  The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease , 2003, Neuropsychopharmacology.

[12]  N. A. Blackburn,et al.  The nighttime problems of Parkinson's disease. , 1988, Clinical neuropharmacology.

[13]  M W Mahowald,et al.  Chronic behavioral disorders of human REM sleep: a new category of parasomnia. , 1986, Sleep.

[14]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[15]  B. Jones,et al.  c‐Fos expression in dopaminergic and GABAergic neurons of the ventral mesencephalic tegmentum after paradoxical sleep deprivation and recovery , 2002, The European journal of neuroscience.

[16]  W. Weiner,et al.  Sleep Disruption in the Course of Chronic Levodopa Therapy: An Early Feature of the Levodopa Psychosis , 1982, Clinical neuropharmacology.

[17]  M. Herrero,et al.  Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression , 2007, Journal of Neural Transmission.

[18]  C. Blaha,et al.  Modulation of dopamine efflux in the striatum following cholinergic stimulation of the substantia nigra in intact and pedunculopontine tegmental nucleus-lesioned rats , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  A. de Weerd,et al.  The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. , 2002, Sleep medicine.

[20]  R. Oades,et al.  Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity , 1987, Brain Research Reviews.

[21]  C. Blaha,et al.  Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat , 2003, The European journal of neuroscience.

[22]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[23]  Erwan Bezard,et al.  Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model , 2009, Experimental Neurology.

[24]  Wiklund Ra,et al.  First of two parts , 1997 .

[25]  R. Chervin,et al.  Decreased striatal dopaminergic innervation in REM sleep behavior disorder , 2000, Neurology.

[26]  M. Silber,et al.  REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century , 2010, Neurology.

[27]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[28]  A. Grosmark,et al.  Dopaminergic Control of Sleep–Wake States , 2006, The Journal of Neuroscience.

[29]  P. Winn Frontal syndrome as a consequence of lesions in the pedunculopontine tegmental nucleus: A short theoretical review , 1998, Brain Research Bulletin.

[30]  P. Derambure,et al.  Vigilance states in a parkinsonian model, the MPTP mouse , 2004, The European journal of neuroscience.

[31]  W. Oertel,et al.  Predictors of sudden onset of sleep in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[32]  B. Jacobs,et al.  Behavioral correlates of dopaminergic unit activity in freely moving cats , 1983, Brain Research.

[33]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[34]  Robert E Burke,et al.  A critical evaluation of the Braak staging scheme for Parkinson's disease , 2008, Annals of neurology.

[35]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[36]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Á. Iranzo Sleep–wake changes in the premotor stage of Parkinson disease , 2011, Journal of the Neurological Sciences.

[38]  S. Noachtar,et al.  Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. , 2003, Sleep.

[39]  E. C. Hirsch,et al.  Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease , 2000, Neuroscience.

[40]  Richard P Allen,et al.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. , 2003, Sleep medicine.

[41]  C. Goetz,et al.  Akathisia in Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[42]  M. M. Lima,et al.  The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation. , 2009, Journal of neural transmission. Supplementum.

[43]  A. Lang,et al.  Akathisia in idiopahic Parkinson's disease , 1987, Neurology.

[44]  K. Chaudhuri,et al.  Sleep-related problems of Parkinson's disease. , 2006, Age and ageing.

[45]  George Maeda,et al.  Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats , 1999, Brain Research.

[46]  S. Tufik,et al.  Blockage of dopaminergic D2 receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation , 2008, Behavioural Brain Research.

[47]  H. Almirall,et al.  Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys , 2001, Neurophysiologie Clinique/Clinical Neurophysiology.

[48]  W. Oertel,et al.  Restless Legs Syndrome (RLS) and Parkinson's disease (PD)—Related disorders or different entities? , 2010, Journal of the Neurological Sciences.

[49]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[50]  G. A. Howell,et al.  Activity of substantia nigra units across the sleep-waking cycle in freely moving cats , 1981, Neuroscience Letters.

[51]  M. Vila,et al.  MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.

[52]  J. Larsen,et al.  Increased risk of leg motor restlessness but not RLS in early Parkinson disease , 2011, Neurology.

[53]  José Luis Molinuevo,et al.  Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study , 2006, The Lancet Neurology.

[54]  C. Tanner,et al.  Excessive daytime sleepiness and subsequent development of Parkinson disease , 2005, Neurology.

[55]  M. Kindt,et al.  Prevention of the Nigrostriatal Toxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine by Inhibitors of 3,4‐Dihydroxyphenylethylamine Transport , 1986, Journal of neurochemistry.

[56]  M. Feenstra,et al.  Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens , 2000, Neuroscience.

[57]  K. Bayles,et al.  A longitudinal study of neuropsychological change in individuals with Parkinson's disease , 2003, International journal of geriatric psychiatry.

[58]  A M Graybiel,et al.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[60]  G. Ebersbach,et al.  Sudden daytime sleep onset in Parkinson's disease: Polysomnographic recordings , 2001, Movement disorders : official journal of the Movement Disorder Society.

[61]  K. Chaudhuri,et al.  Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome , 1999, Acta neurologica Scandinavica.

[62]  Julien Doyon,et al.  Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases , 2006, The Lancet Neurology.

[63]  B. Kocsis,et al.  Prominent Burst Firing of Dopaminergic Neurons in the Ventral Tegmental Area during Paradoxical Sleep , 2007, Neuropsychopharmacology.

[64]  S. Tufik,et al.  The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats , 2007, PloS one.

[65]  Jian Liu,et al.  The firing activity of presumed cholinergic and non-cholinergic neurons of the pedunculopontine nucleus in 6-hydroxydopamine-lesioned rats: An in vivo electrophysiological study , 2008, Brain Research.

[66]  R. Postuma,et al.  Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder , 2006, The Lancet Neurology.

[67]  R. Roos,et al.  Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. , 1994, Archives of neurology.

[68]  J. Jankovic,et al.  Exploring the relationship between Parkinson disease and restless legs syndrome. , 2002, Archives of neurology.

[69]  W. Smeets,et al.  Evolution of the basal ganglia in tetrapods: a new perspective based on recent studies in amphibians , 1998, Trends in Neurosciences.

[70]  M. Vendette,et al.  Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder , 2009, Neurology.

[71]  Marcelo M. S. Lima,et al.  The dopaminergic dilema: Sleep or wake? Implications in Parkinson's disease , 2008 .

[72]  K. Kekesi,et al.  A novel effect of MPTP: the selective suppression of paradoxical sleep in cats , 1990, Brain Research.

[73]  E. V. van Someren,et al.  REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. , 2011, Sleep.

[74]  Emmanuel Roze,et al.  Restoration of normal motor control in Parkinson's disease during REM sleep. , 2007, Brain : a journal of neurology.

[75]  W. Weiner,et al.  Sleep disorders and sleep effect in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[76]  J. Carrier,et al.  REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease , 2002, Neurology.

[77]  M. Vidailhet,et al.  Sleep disturbances in patients with parkinsonism , 2008, Nature Clinical Practice Neurology.

[78]  J W Langston,et al.  Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.

[79]  J. Larsen,et al.  A community‐based study of sleep disorders in patients with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[80]  R. Chervin,et al.  REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA , 2003, Neurology.

[81]  P. Derambure,et al.  The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice , 2007, Brain Research.

[82]  M. Trulson,et al.  Dopamine-containing ventral tegmental area neurons in freely moving cats: Activity during the sleep-waking cycle and effects of stress , 1984, Experimental Neurology.

[83]  I. Arnulf Excessive daytime sleepiness in parkinsonism. , 2005, Sleep medicine reviews.

[84]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[85]  M W Mahowald,et al.  Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. , 2007, Brain : a journal of neurology.

[86]  A. Schapira Restless Legs Syndrome , 2012, Drugs.